In this episode, Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP, and Anne Teitelman, PhD, FNP-BC, FANNP, FAAN, discuss key PrEP considerations for advanced practice providers in primary care settings, including: The importance of having PrEP navigators to help with logistics and be a point of contact for patients Where to find education and resources to familiarize yourself with PrEP and its prescribingSafety considerations and adverse events associated with PrEP optionsPrEP coverage and costHow to discontinue PrEP and the risk of resistance if someone acquires HIV while taking PrEPFacultyTavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaAnne Teitelman, PhD, FNP-BC, FANNP, FAANAssociate Professor Emeritus of Nursing and Global Women’s HealthDepartment of Family and Community HealthSchool of NursingUniversity of PennsylvaniaProfessorThomas Jefferson UniversityCollege of NursingPhiladelphia, PennsylvaniaLink to full program: https://bit.ly/3PZGYdR

In this podcast episode, Mark Brennan-Ing, PhD, and Nina I. Martinez discuss mental health challenges in people living with HIV and much-needed strategies to overcome these challenges to optimize engagement in HIV care, including:The increased rates of mental health disorders and substance use among people living with HIVHow mental health disorders contribute to challenges with adherence to HIV treatment and engagement in careHow social isolation and stigma can affect outcomes despite access to HIV care and ARTThe importance of mental health screenings as part of HIV careIntegrating mental health services into HIV care as a strategy to overcome mental health challenges being a barrier to carePresenter:Mark Brennan-Ing, PhDDirector of Research and EvaluationBrookdale Center for Healthy AgingHunter CollegeThe City University of New YorkNew York, New YorkNina I. MartinezPublic Health ConsultantLink to full program: https://bit.ly/3TqVnl1

In this podcast episode, Isolde Butler, MD, MPH, a healthcare professional caring for people living with HIV, and Marissa Gonzalez, an individual living with HIV, discuss strategies to improve healthcare professionals’ competencies in delivering optimal HIV care from the start to better support patients in overcoming barriers to sustained care engagement.The topics they discuss include: An introduction to the guidelines on ART initiation—start quickly and choose the therapy that is effective and tolerableThe patient experience, from initial diagnosis to treatment selection, noting that where people get diagnosed matters in determining the level of support they will receiveThe complete HIV care team: healthcare professionals, navigators, case managers, behavioral health providers, mental health providers, and so on. Smaller clinics may not be able to provide adequate support to meet all patient needsHow to navigate the first visit after an HIV diagnosis, including patient–provider treatment discussions on the available therapies that can help with stigmaHIV stigma education; navigating the miseducation and misinformationPresenters:Isolde F. Butler, MD, MPHChief Medical OfficerCresentcareNew Orleans, LouisianaMarissa GonzalezChairCommunity Advisory BoardThe Well ProjectLink to full program:https://bit.ly/3TqVnl1

In this podcast episode, Babafemi Taiwo, MBBS, and Vincent Crisostomo discuss the evolving treatment landscape for aging people living with HIV, encompassing the clinical and external resources necessary to support physical and psychosocial health. The topics discussed include:• Mindful prescribing and understanding the impact an HIV diagnosis can have on one’s mental health, including social isolation• How to address patients’ needs and establish a trusting relationship within the confines of a 15-minute clinic visit• How research is helping healthcare professionals better understand this clinical situation and discover opportunities to equalize metrics• The critical role of social workers and community organizations in patients’ overall care• Accessing federal HIV disability resources• Informed patient–provider discussion and counseling on medical decision-making regarding ART• How healthcare professionals can move toward clinical practice that leaves no one behindPresenter:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChiefDivision of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisVincent CrisostomoDirectorAging ServicesSan Francisco AIDS FoundationSan Francisco, CaliforniaLink to full program:https://bit.ly/3TqVnl1 

In this episode, Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discusses data and recommendations for providing HIV prevention options as a strategy to support PrEP persistence and engagement, including: Postexposure prophylaxis (PEP) recommendations and the data for PEP-in-PocketOffering PrEP to everyone who receives PEPCurrently recommended PrEP options and the safety and adverse event considerations with each optionMonitoring recommendations for the different PrEP optionsThe importance of proactively addressing PrEP safety concerns that could lead to PrEP discontinuationFacultyKevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCESAssistant ProfessorPharmacotherapeutics and Clinical ResearchUniversity of South Florida Taneja College of MedicineTampa, FloridaFollow along with the slides:bit.ly/48cULUNLink to full program:bit.ly/3ZlICsL

During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including: A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid Lessons learned from a long-term outcomes study of people with PBCResults from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acidPresenter:Kris V. Kowdley MD, FAASLD, FACP, FACGProfessor, Elson S. Floyd College of MedicineWashington State UniversityDirector, Liver Institute NorthwestSeattle, Washington      Link to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI

In this episode, Dr Tavell Kindall and Jona Tanguay discuss actionable strategies for advanced practice providers to increase the frequency at which PrEP is offered and initiated in primary care settings. Topics covered include:Available training resources on how to offer PrEP in primary careAffordable, accessible PrEP options, including patient assistance programsUsing electronic health records to identify candidates for PrEPOpportunities to offer PrEP during appointments regarding birth control, STIs, or any other sexual health concernsHow to offer 3-site STI testing at your facilityWrapping PrEP into primary careIncorporating navigators or care coordinators to reduce logistical barriers and reach underserved populationsRapid testing, mobile testing, and Tele-PrEP as ways to facilitate PrEP initiation and simplify routine PrEP visitsHealthcare professionals’ personal biases as a potential barrier to PrEPUsing ICD-10 codes for HIV PrEP as a way to further destigmatize PrEP and simplify billingFaculty:Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaJona Tanguay, MMSc, PA-C, AAHIVSMedical Program Lead - Substance Use Disorders at Whitman-Walker HealthAssociate Medical Director - Transgender Health at Amida CarePresident-Elect at GLMA: Health Professionals Advancing LGBTQ+ EqualityClinical Instructor at Yale School of MedicineFounder at ChemsexHarmReduction.orgWashington, DCContent is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

In this third of 3 episodes, global HIV experts and advocates discuss the current status of HIV cure research, including key concepts to understand and communicate when counselling patients, colleagues, and the broader community on HIV cure: Latest understanding of the viral reservoirNew insights and questions on the best timing for cure interventionsCurrent investigational strategies showing promiseEthical considerations related to participant education, representation in clinical trials, and planning for broad global accessFaculty: Katharine J. Bar, MDAssociate Professor of MedicineDirector, Penn CFAR Virus and Reservoirs CoreUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJennifer Blanchette, PhDIndependent ContractorClinical Care OptionsColorado, United StatesKrista L. Dong, MDClinical Director, FRESH CohortAssistant Professor of MedicineMassachusetts General HospitalHarvard Medical SchoolBoston, MassachusettsKarine Dubé, DrPH, MPhilAssociate ProfessorUCSD School of MedicineDivision of Infectious Diseases and Global Public HealthSan Diego, CaliforniaRichard JefferysBasic Science, Vaccines & Cure Project DirectorTreatment Action GroupNew York, New YorkSharon R. Lewin, AO, FRACP, PhD, FAA, FAHMSDirectorDoherty InstituteMelbourne Laureate Professor and HeadDepartment of Infectious DiseasesThe University of MelbourneConsultant PhysicianVictorian Infectious Diseases ServiceRoyal Melbourne HospitalConsultant Physician and Adjunct Professor Department of Infectious DiseasesAlfred Hospital and Monash UniversityMelbourne, AustraliaAngelina Namiba Founder Member4M Network of Mentor MothersLondon, United KingdomLink to full program:https://bit.ly/3QFwv7n

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:Burden of CRE infections in the United StatesMechanisms of resistanceChanging epidemiologyUse of rapid diagnostic testsIDSA guidance recommendations, including supporting dataApproach to designing treatment regimens, including weighing patient- and infection-related factorsFaculty:Julie Ann Justo, PharmD, MS, FIDSA, BCPSClinical Pharmacist Lead – Infectious DiseasesInpatient PharmacyDartmouth Hitchcock Medical CenterLebanon, New HampshireLink to full program: https://bit.ly/41a8Mj0Link to accompanying ClinicalThought commentary:https://bit.ly/4865T57Link to downloadable infographic: https://bit.ly/3t7NpT2

In this episode, Errol L. Fields, MD, PhD, MPH, and Armonté Butler, MPH, a pre-exposure prophylaxis (PrEP) advocate, discuss strategies for overcoming barriers to uptake of PrEP for HIV in adolescents and young adults, based on the unique needs of this patient population. Topics covered include:Methods for building trust between patients and providersWays to practice shared decision-making and how this process hinges on respecting patients’ autonomy and personhoodHow to empower young people to ask for the assistance they needHow to navigate consent and confidentiality issuesInformation about payment optionsStrategies to improve adherence for youthThe best ways to provide support and flexibility throughout this process to promote persistence on PrEP Faculty:Errol L. Fields, MD, PhD, MPHAssociate Professor of PediatricsDivision of Adolescent/Young Adult MedicineDepartment of PediatricsJohns Hopkins School of MedicineBaltimore, MarylandArmonté Butler, MPHAssociate Director, LGBTQ Health & RightsAdvocates for YouthWashington, DCContent is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including: A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acidA study that explored racial differences as they relate to the presentation and diagnosis of PBCPresenter: Stuart C. Gordon, MD, FAASLDDirector of HepatologyHenry Ford Health SystemProfessor of MedicineWayne State University School of MedicineDetroit, MichiganLink to commentary:https://bit.ly/3GzRMt2Link to reviews of other PBC studies from AASLD 2023:https://bit.ly/3RvXXEI

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including: A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)A study that evaluated the effectiveness and safety of second-line therapy in PBC where obeticholic acid with or without a fibrate was added to the treatment regimen of people with PBC with an incomplete response to UDCAA retrospective review of the rates of hyperlipidemia, atherosclerosis, and/or hepatic steatosis in patients with PBCPresenter: Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasLink to commentary:https://bit.ly/47PmGdcLink to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI

In this episode, Martin Rios discusses how pre-exposure prophylaxis (PrEP) persistence depends on healthcare professional knowledge, including:Their own experiences with the various PrEP providers they have seenThe relief that has come with seeing PrEP providers who are supportive and knowledgeable about the different PrEP optionsThe challenges that have come with seeing PrEP providers who are unwilling to prescribe PrEP altogether or who will prescribe PrEP when asked but are not knowledgeable about the optionsFaculty: Martin RiosPrEP User and AdvocatePhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3ZlICsL

In this episode, Meredith Clement, MD, and Whitney C. Irie, MSW, PhD, discuss key considerations for pre-exposure prophylaxis (PrEP) uptake in cisgender women, including: How to incorporate conversations on PrEP during a short clinic visit Helpful resources about PrEP to share with patientsLeveraging clinic staff to improve PrEP uptake and persistence Available data on on-demand PrEPApproach to discussing PrEP contraindications and adverse events with patientsConsiderations for PrEP in pregnant persons or those wanting to conceive The importance of inclusiveness in PrEP marketing Key barriers limiting PrEP uptake in cisgender women (eg, stigma, risk perception)Interventions to improve PrEP uptakeFacultyMeredith Clement, MDAssociate Professor Infectious Diseases Louisiana State University Health Sciences CenterNew Orleans, Louisiana Whitney C. Irie, MSW, PhDAssistant ProfessorDepartment of Social WorkBoston CollegeBrighton, Massachusetts Link to full program: https://bit.ly/3PZGYdR

In this episode, Helen Y. Chu, MD, MPH, shares updates on RSV seasonality, including: Surveillance limitations due to the testing availability in adultsCurrent 2023/2024 season trends, including predictions for other respiratory viruses (eg, influenza, SARS-CoV-2)Considerations for RSV administrationRSV vaccine coadministration with influenza and COVID-19 vaccinesFaculty:  Helen Y. Chu, MD, MPHAssociate Professor of MedicineDivision of Allergy & Infectious DiseasesUniversity of Washington School of MedicineSeattle, WashingtonLink to full program: https://bit.ly/3nb25xeLink to downloadable slides: https://bit.ly/3TsXym5

In this episode, Rick Zimmerman, MD, MPH, FAAFP, discusses RSV vaccines in older adults, including: Breakthroughs in RSV vaccine developmentRSV vaccine snapshot in older adultsFDA-approved RSV vaccines for older adultsCDC evidence to recommendations framework for vaccinesRSV burden in older populationsBenefits and harms of RSV vaccinationRSV vaccine efficacy and safety in older adultsCDC Advisory Committee Immunization Practices recommendations for RSV vaccines in older adultsPopulations at high risk for severe RSV diseaseVaccination considerations based on the upcoming RSV seasonFaculty:Richard Zimmerman, MD, MPH, FAAFPProfessorDepartment of Family Medicine and Clinical Epidemiology  University of PittsburghPittsburgh, PennsylvaniaContent based on an online CME program supported by an independent educational grant from GlaxoSmithKline.Link to full program: https://bit.ly/49YBZ4rLink to downloadable slides: https://bit.ly/3GocjRe

In this episode, Angela Branche, MD; Pamela Rockwell, DO, FAAFP; and Richard Zimmerman, MD, MPH, FAAFP, discuss the clinical presentation of RSV in older adults and available diagnostic tests for RSV, including: Comparison of RSV clinical symptoms to influenza and COVID-19, including differentiating symptoms at infection onsetRSV disease progression RSV diagnostic approaches How RSV diagnosis of adults may differ from diagnosis of childrenClinical considerations for RSV testingHow to improve RSV awareness among patientsProgram Director:Pamela Rockwell, DO, FAAFPProfessorFamily MedicineUniversity of Michigan Medical SchoolAnn Arbor, MichiganFaculty:Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkRichard Zimmerman, MD, MPH, FAAFPProfessorDepartment of Family Medicine and Clinical Epidemiology University of PittsburghPittsburgh, PennsylvaniaContent based on an online CME program supported by an independent educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/49YBZ4rLink to downloadable slides: https://bit.ly/3GocjRe

In this episode, Samantha V. Hill, MD, MPH, and Eunice E. Radcliff, MD, discuss key considerations for PrEP uptake in adolescents, including: Advice on talking with parents about the importance of adolescents having alone time with their healthcare professionalsMaintaining confidentiality when someone is on their parents’ insuranceStrategies to increase awareness, uptake, engagement, and persistence on PrEP among adolescentsHaving discussions about HIV prevention and PrEP along with the HPV vaccine, STI testing, or contraceptionFacultySamantha V. Hill, MD, MPHAssistant ProfessorDivision of General PediatricsSection on Adolescent HealthDepartment of PediatricsEmory UniversityAtlanta, GeorgiaEunice E. Radcliff, MDAssistant Professor General PediatricsEmory University School of MedicineAtlanta, GeorgiaLink to full program: https://bit.ly/3PZGYdR

In this episode, Jean-Michel Molina, MD, PhD, discusses the data and recommendations for considering on-demand PrEP as a strategy to support PrEP persistence and engagement for men who have sex with men, including:Nondaily PrEP options recommended for cisgender menData from the ANRS IPERGAY study evaluating on-demand FTC/TDF vs placebo in men who have sex with menReal-world data on the effectiveness of on-demand PrEPConsiderations for on-demand FTC/TDF in people with renal dysfunctionData on hypertension and statin initiation risk with FTC/TAF PrEPData on weight gain with the different PrEP optionsFacultyJean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and LariboisièreParis, FranceFollow along with the slideshttps://bit.ly/47VGZVLLink to full program:https://bit.ly/3ZlICsL

Should quantitative HBsAg testing be used routinely in clinical practice for patients living with chronic hepatitis B?In this episode, Tatyana Kushner, MD, MSCE, discusses the role of quantitative hepatitis B surface antigen testing in people living with chronic hepatitis B, including:Determination of inactive carrier statusPrediction of liver fibrosis/cirrhosisPrediction of hepatocellular carcinoma developmentMonitoring response to treatment, including future HBV treatments in the development pipelinePrediction of HBsAg lossJoining her for the panel discussion are Ira M. Jacobson, MD, and Paul Y. Kwo, MD.Presenters:Ira M. Jacobson, MDProfessor of MedicineDirector of HepatologyNYU Langone HealthNew York, New YorkTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of Medicine Director of Hepatology Stanford University School of MedicinePalo Alto, CaliforniaLink to the full program: https://bit.ly/3R1PMi4Link to the slides: https://bit.ly/3N5Fpsm

Are we treating HBV early enough? Is it time to move the goalposts regarding the timing of treatment initiation? What are the potential benefits of earlier treatment?To answer these questions, Ira M. Jacobson, MD, leads a panel discussion with Tatyana Kushner, MD, MSCE, and Paul Y. Kwo, MD, exploring which patients with HBV we should be treating, including a focus on:Guideline-based treatment recommendations and their limitationsData describing the relationship between viral suppression and HBV DNA integrationMore expansive indications for HBV treatment based on virologic considerationsPresenters:Ira M. Jacobson, MDProfessor of MedicineDirector of HepatologyNYU Langone HealthNew York, New YorkTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of Medicine Director of Hepatology Stanford University School of MedicinePalo Alto, CaliforniaLink to the full program: https://bit.ly/3R1PMi4Link to the slides: https://bit.ly/3N5Fpsm

In this episode, Angela Branche, MD; Pamela Rockwell, DO, FAAFP; and Rick Zimmerman, MD, MPH, FAAFP, discuss the burden of RSV in older adults, including:RSV burden throughout lifeRSV seasonality in the United StatesComparative burden and incidence of RSV and influenza in adults aged 65 years or olderCardiopulmonary hospitalizations of long-term care facility residents with influenza and/or RSVRisk factors for severe RSV (eg, hospitalization, mortality) in older adultsRSV incidence by presence of underlying medical conditionsRSV awareness among healthcare professionals and patients Program Director:Pamela Rockwell, DO, FAAFPProfessorFamily MedicineUniversity of Michigan Medical SchoolAnn Arbor, MichiganFaculty:Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkRichard Zimmerman, MD, MPH, FAAFPProfessorDepartment of Family Medicine and Clinical Epidemiology  University of PittsburghPittsburgh, PennsylvaniaContent based on an online CME program supported by an independent educational grant from GlaxoSmithKline.Link to full program: https://bit.ly/49YBZ4rLink to downloadable slides: https://bit.ly/3GocjRe 

In this episode, Beatriz Grinsztejn, MD, PhD, discusses the data and recommendations for addressing social determinants as a strategy to support PrEP persistence and engagement for transgender women, including: HIV prevalence among transgender womenData on the PrEP cascade from the PrEParadas study of daily FTC/TDF among transgender womenData from the ImPrEP Study on early loss to follow-up, adherence, long-term engagement, and HIV incidence among transgender womenBarriers to PrEP uptake and adherence for transgender womenDrug–drug interactions between PrEP and feminizing hormone therapyIncreasing PrEP uptake and retention with peer health navigation for transgender womenFacultyBeatriz Grinsztejn, MD, PhDDirectorHIV/STI Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilIAS President-ElectLink to full program:https://bit.ly/3ZlICsL

In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman provide practical strategies for implementing RSV vaccination into practice, including: Educating older adults on RSV vaccinesProviding effective, evidence-based recommendationsShared decision-makingIdentifying and addressing vaccine hesitancyProactive strategies in vaccinating for RSVPredicting and overcoming barriers to RSV vaccinationPresenters:Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyChristina M. Madison, PharmD, FCCP, AAHIVPClinical PharmacistFounder and CEO, The Public Health Pharmacist, PLLCAdjunct Associate Professor of Pharmacy PracticeRoseman University of Health SciencesCollege of PharmacyHenderson, NevadaOther program activities: Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role https://bit.ly/49GUv1gLink to CME: Claim Credit – https://bit.ly/3uoY7VH[After selecting the “Continue to Post Test” button:]To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.

In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman discuss the latest practical strategies for preventing RSV infection in older adults, including: Role of basic public health precautionsAvailable and emerging vaccines Mechanisms of action, therapeutic targets, and pharmacologyEfficacy and safety dataFDA approval status and ACIP recommendations Presenters:  Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyChristina M. Madison, PharmD, FCCP, AAHIVP  Clinical PharmacistFounder and CEO, The Public Health Pharmacist, PLLCAdjunct Associate Professor of Pharmacy PracticeRoseman University of Health SciencesCollege of PharmacyHenderson, NevadaOther program activities:  • Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role     

In this accredited podcast episode, Dr Mary Bridgeman discusses the most important things for pharmacists across all settings to know about RSV infections in patients 60 years of age or older, including: Incidence and prevalence of RSV in older adults, including hospitalization, mortality, epidemiologySeasonalityClinical manifestationsRisk factors for severe outcomesVulnerable groups and comorbiditiesPresenter:Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyOther program activities: Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role https://bit.ly/49GUv1gLink to CME: Claim Credit – https://bit.ly/47GtNnK[After selecting the “Continue to Post Test” button:]To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.

In this episode, Aniruddha (Anu) Hazra, MD, and Ofole Mgbako, MD, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: Data on drug–drug interactions between PrEP options and gender-affirming hormone therapyContributing factors to inequities in PrEP uptake for Black and Latino individualsData on FTC/TAF PrEP for transgender individualsHow to decide whether to do an oral lead-in before starting injectable cabotegravir PrEPTime to effectiveness after starting PrEP PrEP resources available for transgender communities, especially regarding stigmaIntegration of PrEP with gender-affirming hormone therapyStrategies to increase PrEP uptake, specifically in the southCounseling patients on drug–drug interactions, adverse events, and transmission risk when starting PrEPInvolving PrEP navigators in the care of people receiving PrEPSupporting PrEP adherence and retention in careThe use of DoxyPEP in transgender individuals receiving PrEPFacultyAniruddha (Anu) Hazra, MDAssistant Professor, Section of Infectious Disease and Global HealthDirector, Infectious Diseases Fellowship ProgramMedical Director, UCM Sexual Wellness ClinicDirector of STI Services, Chicago Center of HIV EliminationDepartment of MedicineUniversity of ChicagoChicago, IllinoisOfole Mgbako, MDAssistant Professor of Medicine and Population Health  Section Chief of Infectious DiseaseBellevue HospitalClinical Pillar Lead, NYU Institute for Excellence in Health EquityNYU Grossman School of MedicineNYU Langone HealthNew York, New YorkLink to full program: https://bit.ly/3PZGYdR

In this episode,Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections caused by NDM-producing Enterobacterales, including: Ambler classification of β-lactamasesMechanisms of resistance2023 IDSA guidance recommendationsThe latest clinical data by antimicrobial regimen:Ceftazidime/avibactam and aztreonamCefiderocolInvestigational aztreonam/avibactamClinical case of NDM-producing E. coli with pan-β-lactam resistanceProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program:https://bit.ly/40HyvPy

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including: Mechanisms of β-lactam resistanceEffect of resistance mechanism on susceptibility to antipseudomonal agent2023 IDSA guidance recommendations Activity against newer antipseudomonal β-lactams in the United StatesThe latest clinical data by antimicrobial regimen:              - Ceftolozane/tazobactam              - Ceftazidime/avibactam              - Imipenem/cilastatin/relebactam              - CefiderocolApplying antimicrobial stewardship principlesProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP  Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland  School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical Center|Baltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine  Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://clinicaloptions.com/CE-CME/infectious-disease/cmv-prevention-in-sot-recipients/26139Link to full program: https://bit.ly/40HyvPy 

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: Mechanisms for β-lactam resistanceAdditional resistance mechanisms and virulence factors2023 IDSA guidance recommendations for moderate to severe CRAB infectionsThe latest clinical data by antimicrobial therapy/regimen:SulbactamMeropenem and colistinCarbapenem, sulbactam, and polymyxin BTetracyclinesCefiderocolSulbactam/durlobactam and carbapenems Program Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/40Mmicz

In this second of 3 episodes, global HIV experts and advocates discuss how HIV care can better meet the diverse needs of people living with HIV as new treatment strategies emerge and continue to evolve, including:How the emergence of long-acting injectable HIV treatment has been a game-changer for many people living with HIVEmerging strategies that are expanding the application of long-acting ART to address unmet treatment needsPotential for future innovations in ART that are hoped will further address unmet needs and preferences of people living with HIVFaculty: Ann Avery, MDProfessor of MedicineCase Western Reserve UniversityDivision of Infectious DiseasesMetroHealth Medical CenterCleveland, OhioJennifer Blanchette, PhDIndependent ContractorClinical Care OptionsColorado, United StatesIsolde Butler, MD, MPHChief Medical OfficerCrescentCareNew Orleans, LouisianaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineDirector, Center for AIDS Research (CFAR)Medical Director, Ward 86 HIV ClinicUniversity of California, San Francisco (UCSF)San Francisco, CaliforniaMarissa GonzalezChair Community Advisory Board The Well ProjectAngelina Namiba Founder Member4M Network of Mentor MothersLondon, United KingdomChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesFaculty of Medicine and DentistryQueen Mary University of LondonBlizard InstituteBarts Health NHS TrustLondon, United KingdomLink to full program:https://bit.ly/3QFwv7nLinks to programs discussed in the episode:www.4mmm.org

In this episode, global PrEP experts and advocates discuss how current PrEP regimens represent a revolutionary step forward in enabling many individuals to avoid HIV acquisition, including: How PrEP has empowered people to take control of their sexual lives, revolutionized people’s sexual experiences, and, for some, improved their experiences with healthcare in generalThe extraordinary progress that has been made in New South Wales and specifically in inner Sydney toward HIV transmission elimination and the role of PrEP in the prevention of new HIV infectionsThe importance of having PrEP options, including on-demand options and long-acting formulations, available to different populations who could benefit to see progress toward HIV transmission elimination globallyFaculty: Jessica L. Adams, PharmD, AAHIVEScientific Director, Infectious DiseasesClinical Care OptionsNew York, United StatesLinda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV CentreUniversity of Cape TownSouth AfricaChief Executive OfficerThe Desmond Tutu Health FoundationCape Town, South AfricaKenyon R. FarrowPrEP AdvocateVice President of PolicyPoint Source YouthContributing EditorTheBody.comOhio, United StatesBeatriz Grinsztejn, MD, PhDDirectorSTI/AIDS Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilAndrew Grulich, MBBS, PhDScientia ProfessorHead, HIV Epidemiology and Prevention ProgramThe Kirby InstituteUniversity of New South Wales, SydneyNew South Wales, AustraliaJean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and LariboisièreParis, FranceBrittany Williams, PhDPrEP AdvocateAssistant Professor of Higher Education and Student Affairs AdministrationDepartment of Education University of Vermont Vermont, United StatesLink to full program: https://bit.ly/3FbPBey

In this episode, global PrEP experts and advocates discuss barriers that have prevented the full potential of today’s PrEP regimens from being delivered, how those barriers might be overcome, and how the next generation of PrEP modalities may address unmet needs, including: How access and implementation of PrEP have limited its benefit and led to disparities in uptake among racial and ethnic groups in the United States and among key populations globallyThe challenges of adherence to PrEP for healthy individuals who are required to consistently take medication and engage with the healthcare system when they aren’t sickThe potential for longer-acting PrEP modalities and a greater number of PrEP options for individuals in the future to expand PrEP uptake and adherence with equitable global accessFaculty: Jessica L. Adams, PharmD, AAHIVEScientific Director, Infectious DiseasesClinical Care OptionsNew York, United StatesLinda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV CentreUniversity of Cape TownSouth AfricaChief Executive OfficerThe Desmond Tutu Health FoundationCape Town, South AfricaKenyon R. FarrowPrEP AdvocateVice President of PolicyPoint Source YouthContributing EditorTheBody.comOhio, United StatesBeatriz Grinsztejn, MD, PhDDirectorSTI/AIDS Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilBrittany Williams, PhDPrEP AdvocateAssistant Professor of Higher Education and Student Affairs AdministrationDepartment of Education University of Vermont Vermont, United StatesLink to full program: https://bit.ly/3FbPBey

In this episode, Lilly C. Lee, MD, SM, FACEP, FAAEM, discusses the best practices in management of uUTI in the emergency department, including:Patient triageDiagnostic stewardshipInterdisciplinary careStrategies to overcome treatment barriersPresenter:Lilly C. Lee, MD, SM, FACEP, FAAEMChief of Emergency MedicineJackson Memorial HospitalFlorida Poison Information CenterRoxcy Bolton Rape Treatment CenterAffiliated Assistant Professor of SurgeryDeWitt Daughtry Family Department of SurgeryLeonard M. Miller School of MedicineUniversity of MiamiMiami, FloridaFind other program activities here: “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsSlides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsPodcast 1: Burden on Uncomplicated Urinary Tract InfectionsPodcast 2: Updates in Antimicrobial Selection for uUTIsClinicalThought: When Care Gets Complicated: Uncomplicated UTI Management in Acute Care Settings 

In this episode, Richard Colgan, MD, discusses the burden of uncomplicated UTIs (uUTIs) and best practices in their management, including:Accurate diagnosis and classificationRisk factors for uUTIs and treatment failureBurdens of uUTIs on patientsInnovations in care, including self-diagnosis and virtual managementThe importance of avoiding screening and management of asymptomatic bacteriuria in most patientsWe will also hear from a patient who details the impact of uUTI on her quality of life. Presenter:Richard Colgan, MD​Executive Vice ChairProfessor of Family and Community MedicineUniversity of Maryland School of MedicineBaltimore, MarylandFind other program activities here: “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsSlides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsPodcast 2: Updates in Antimicrobial Selection for uUTIsPodcast 3: When Things Get Complicated: Managing uUTIs in Acute CareClinicalThought: Uncomplicated but Not Insignificant: The Burden of Uncomplicated UTIs 

In this episode, Lillian Abbo, MD, MBA, FIDSA, discusses appropriate antimicrobial selection for managing uncomplicated UTIs, including:Balancing discrepancies in available guidelines Individualizing antimicrobial selection based on patient characteristics and local resistance patterns Incorporating tools, like antibiograms, into daily practice Being a good steward of currently available antimicrobial agents Planning ahead for emerging therapies for uncomplicated UTIsPresenter:Lillian Abbo, MD, MBA, FIDSAAssociate Chief Medical Officer Infectious DiseasesJackson Health SystemProfessor of Clinical Infectious DiseasesUniversity of Miami Miller School of MedicineMiami Transplant InstituteMiami, FloridaFind other program activities here: “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsSlides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsPodcast 1: Burden on Uncomplicated Urinary Tract InfectionsPodcast 3: When Things Get Complicated: Managing uUTIs in Acute CareClinicalThought: Not Always an Easy Task: Antimicrobial Stewardship for Uncomplicated UTIs

In this episode, Atul Humar, MD, FRCP(C); Hannah Imlay, MD, MS; and Raymund Razonable, MD, discuss cytomegalovirus (CMV) management strategies in solid organ transplantation recipients, including:Evaluation of current data on CMV prevention in liver transplant recipientsPractical considerations for switching an institution’s antiviral therapy of choice for primary prophylaxisBarrier of resistance to antiviral therapiesFactors to consider when deciding CMV treatment durationUse of lymphocyte count to assess CMV cell–mediated immunityProgram Director:Atul Humar, MD, FRCP(C)Professor of MedicineUniversity of Toronto  Director, Ajmera Transplant CentreUniversity Health NetworkR. Fraser Elliott Chair in TransplantationDirector University of Toronto Transplant InstituteToronto, Ontario, CanadaFaculty:Hannah Imlay, MD, MSAssistant Professor of MedicineDepartment of Internal Medicine, Division of Infectious DiseasesUniversity of Utah  Salt Lake City, UtahRaymund Razonable, MDProfessor of MedicineProgram Director, Infectious Diseases FellowshipVice Chair, Division of Infectious DiseasesMayo ClinicRochester, Minnesota  Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K

In this episode, Hannah Imlay, MD, MS, discusses cytomegalovirus (CMV) prevention strategies in solid organ transplantation (SOT) recipients including:Strategies for preventing CMV in SOTInternational guideline recommendations for CMV prevention strategies by organ typeAntivirals used for CMV preventionComparison of preemptive therapy vs prophylaxis for CMV prevention in liver transplant recipientsComparison of letermovir vs valganciclovir for CMV prophylaxis in kidney transplant recipientsUse of CMV cell–mediated immunity monitoring for primary prophylaxisMonitoring CMV viral loads, including limitations to quantitative nucleic acid testingFuture prevention approachesFaculty:Hannah Imlay, MD, MSAssistant Professor of MedicineDepartment of Internal Medicine, Division of Infectious DiseasesUniversity of Utah  Salt Lake City, UtahContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K

In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:CMV treatment goals CMV treatment and monitoring recommendationsRole of secondary prophylaxisUse of CMV cell–mediated immunity (CMI) monitoring for CMV relapse riskUse of CMV CMI for secondary prophylaxis Proposed use of CMV CMI monitoring for secondary prophylaxisIncidence and outcomes with antiviral resistance Risk factors for CMV resistanceWhen to suspect antiviral resistance Testing for antiviral resistance using genotypic assaysOutcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virusTreatment recommendations for resistant/refractory CMVEfficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE studyTreatment algorithm for resistant/refractory CMV Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV Faculty:Raymund Razonable, MDProfessor of MedicineProgram Director, Infectious Diseases FellowshipVice Chair, Division of Infectious DiseasesMayo ClinicRochester, Minnesota Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K

Arthur Kim, MD, and Renslow Sherer, MD, discuss how new data on COVID-19 vaccines and treatments may affect practice, including:Real-world data on COVID-19 outcomesCOVID-19 prevention: current and emerging conceptsCOVID-19 therapeutics: new clinical trial and real-world dataPresenters:Arthur Kim, MDAssociate Professor of MedicineHarvard Medical SchoolDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisFollow along with the slides at:https://bit.ly/40DFjhvLink to full program: https://bit.ly/3FI8HJx

In this first of 3 episodes, global HIV experts and advocates discuss how innovative models of care are minimizing barriers to HIV care engagement to improve uptake by key underserved populations, including:How peer support programs empower people to combat stigma, become more educated about treatment, and be engaged participants in their HIV careStrategies for addressing potential unmet mental healthcare needs among people living with HIVApproaches to reengage people with HIV who transit through county jail systemsHow integrated care strategies and wrap-around services can overcome some of the barriers to care that are associated with social determinants of healthKey considerations when providing HIV care for migrant and refugee populations Faculty:Ann Avery, MDProfessor of MedicineCase Western Reserve UniversityDivision of Infectious DiseasesMetroHealth Medical CenterCleveland, OhioJennifer Blanchette, PhDIndependent ContractorClinical Care OptionsColorado, United StatesIsolde Butler, MD, MPHChief Medical OfficerCrescentCareNew Orleans, LouisianaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineDirector, Center for AIDS Research (CFAR)Medical Director, Ward 86 HIV ClinicUniversity of California, San Francisco (UCSF)San Francisco, CaliforniaMarissa GonzalezChairCommunity Advisory BoardThe Well ProjectAngelina NamibaFounder Member4M Network of Mentor MothersLondon, United KingdomChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesFaculty of Medicine and DentistryQueen Mary University of LondonBlizard InstituteBarts Health NHS TrustLondon, United KingdomMiłosz Parczewski, MD, PhDProfessor of MedicineDepartment HeadConsultant in Infectious DiseasesDepartment of Infectious, Tropical Diseases and Acquired ImmunodeficiencyPomeranian Medical UniversitySzczecin, PolandLink to full program:https://bit.ly/3QFwv7nLinks to programs discussed in the episode:https://4mmm.org/https://positivepeers.org/  

In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G

In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:Mycobacterium avium complexM. kansasiiM. xenopiWe will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G 

In this episode, Pamela J. McShane, MD, describes the 3 pillars for nontuberculous mycobacterial (NTM) lung disease diagnosis:Clinical symptomsRadiographic evidenceMicrobiologic dataWe will also hear from a patient who details his diagnostic journey and will hear Dr. McShane discuss an illustrative clinical case.Presenter: Pamela J. McShane, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine The University of Texas Health Science Center at Tyler Tyler, Texas Link to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G

In this episode, David Alain Wohl, MD, discusses key considerations to PrEP barriers in cisgender women, including:Prevalence of PrEP use in the USBarriers to PrEP uptake PrEP efficacy based on adherenceInterventions to support PrEP adherenceRecommended PrEP regimens, including considerations for use in pregnancy and breastfeeding Presenter: David Alain Wohl, MDProfessor of MedicineSchool of MedicineSite Leader, Global Infectious Diseases Clinical Trials UnitUniversity of North Carolina at Chapel Hill Chapel Hill, North Carolina Content based on an online CME program supported by an independent educational grant from ViiV Healthcare. Link to full program: https://bit.ly/3ZpM6uuFollow along with the slides: https://bit.ly/3LyGgBj

In this podcast, experts Sarah M. Wood, MD, MS, and Errol L. Fields, MD, PhD, MPH, discuss some of the challenges and concerns clinicians face when prescribing PrEP to adolescents. The faculty addresses the potential for adverse effects from PrEP, including the potential for renal impairment, decreased bone density, and whether PrEP can interfere with hormone therapy for gender-affirming care. They review the data behind these concerns and emphasize that the vast majority of adverse effects caused by PrEP are mild and reversible.The experts also examine common barriers that adolescents face when attempting to initiate and adhere to PrEP, such as insurance coverage and confidentiality. Dr Fields and Dr Woods discuss strategies for overcoming these barriers and retaining adolescents on PrEP, including how to navigate tricky conversations with both patients and parents or within communities that may stigmatize PrEP and HIV.Sarah M. Woods, MD, MSAssistant Professor of PediatricsDivision of Adolescent MedicineUniversity of Pennsylvania Perelman School of MedicineChildren’s Hospital of PhiladelphiaPhiladelphia, PennsylvaniaErrol L. Fields, MD, PhD, MPHAssociate Professor of PediatricsDivision of Adolescent/Young Adult MedicineDepartment of PediatricsJohns Hopkins School of MedicineBaltimore, MarylandContent based on an online CME program supported by independent educational grants from Gilead Sciences Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

In this episode, we hear from 2 people living with HIV: Melanie Reese from the United States and Marc Thompson from the United Kingdom. Both Melanie and Marc have done important work in the HIV field as patient advocates. Today, they will be discussing their experiences in accessing and navigating their own HIV care, with a focus on some of the barriers that can complicate and even block a person's journey across the HIV care continuum. In reviewing these challenges, Marc and Melanie share their insights on key strategies that can help to facilitate HIV care for patients, making the experience more straightforward and minimizing the impact that HIV has on their daily lives. Presenters:Melanie ReeseSubject Matter Expert, Older Women Living and Aging with HIV, HIV North America Health Resources and Services Administration HIV/AIDS BureauExecutive Director, Older Women Embracing LifeBoard Secretary, International Community of Women Living with HIVBaltimore, MarylandMarc ThompsonDirector, The Love TankCo-founder, PrepsterLondon, EnglandContent based on an online CME/CPE/CE program supported by an independent educational grant from Gilead Sciences, Inc. Link to full program:https://bit.ly/3Pas4zn

In this podcast, expert Rasika Karnik, MD, MS, discusses how to manage the health risks posed by COVID-19 infection and long COVID in individuals with metabolic syndrome or obesity.Dr Karnik discusses the interplay between COVID-19 outcomes, obesity/metabolic syndrome, and social determinants of health and delves into detail on how to address and mitigate these social determinants of health in a high-risk population.Presenters:Rasika Karnik, MD, MSAssistant ProfessorDivision of Primary Care, Department of Internal MedicineUniversity of ChicagoChicago, IllinoisContent based on an online CME program supported by independent educational grants from Pfizer.Link to full program: https://bit.ly/46yuChS